Aliskiren Hemifumarate

半延胡索酸阿利吉仑

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameAliskiren Hemifumarate
Drug Alias Name阿利克仑半富马酸盐Rasilles富马酸阿利克仑aliskirenoaliskirenum +[16] 
ClassificationSmall molecules
Mechanisms of ActionRenin inhibitors
TargetsRenin
Therapy Area/IndicationsDiabetic macular oedemaOverweightDiabetes Mellitus, Type 2 +[15] 
Global Approved IndicationsEssential HypertensionHypertension
Approved Indications in ChinaEssential Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2007/03/05
Country/TerritoryCzechiaBelgiumCanada +[46] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesLXO GroupNoden Pharma DacNovartis Pharma Ag
Inactive CompaniesChinese University Of Hong Kong (Cuhk)Novartis Pharma Schweiz AgNovartis Pharma Stein Ag +[6] 
Active IndicationsEssential HypertensionHypertension
Inactive IndicationsDiabetic macular oedemaOverweightDiabetes Mellitus, Type 2 +[13] 

Other Information

ATC CodeC09XA02
Related LinksWikipediaDrugBankKEGG